REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 3 filers reported holding REATA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $31,120,741 | +37.5% | 305,225 | +22.6% | 0.00% | +200.0% |
| Q1 2023 | $22,636,368 | +55.1% | 248,970 | -35.2% | 0.00% | 0.0% |
| Q4 2022 | $14,591,047 | +12.6% | 384,076 | -25.5% | 0.00% | 0.0% |
| Q3 2022 | $12,964,000 | -19.4% | 515,881 | -2.6% | 0.00% | -50.0% |
| Q2 2022 | $16,093,000 | +18.5% | 529,550 | +27.7% | 0.00% | +100.0% |
| Q1 2022 | $13,584,000 | +123.3% | 414,661 | +79.8% | 0.00% | – |
| Q4 2021 | $6,082,000 | -92.6% | 230,640 | -71.8% | 0.00% | -100.0% |
| Q3 2021 | $82,265,000 | -22.5% | 817,665 | +9.0% | 0.01% | -12.5% |
| Q2 2021 | $106,139,000 | +1647.1% | 749,933 | +1130.8% | 0.01% | +700.0% |
| Q1 2021 | $6,075,000 | -89.9% | 60,932 | -87.4% | 0.00% | -80.0% |
| Q4 2020 | $59,960,000 | +25.0% | 485,032 | -1.5% | 0.01% | 0.0% |
| Q3 2020 | $47,971,000 | -64.5% | 492,416 | -43.2% | 0.01% | -66.7% |
| Q2 2020 | $135,246,000 | +29.0% | 866,848 | +19.3% | 0.02% | 0.0% |
| Q1 2020 | $104,845,000 | +42.9% | 726,370 | +102.3% | 0.02% | +87.5% |
| Q4 2019 | $73,384,000 | +727.9% | 358,968 | +225.1% | 0.01% | +700.0% |
| Q3 2019 | $8,864,000 | +92.5% | 110,403 | +126.2% | 0.00% | 0.0% |
| Q2 2019 | $4,604,000 | -66.7% | 48,797 | -69.8% | 0.00% | -50.0% |
| Q1 2019 | $13,820,000 | -19.9% | 161,697 | -47.4% | 0.00% | 0.0% |
| Q4 2018 | $17,256,000 | -44.0% | 307,597 | -18.3% | 0.00% | -33.3% |
| Q3 2018 | $30,791,000 | +87.7% | 376,597 | -19.7% | 0.00% | +50.0% |
| Q2 2018 | $16,401,000 | +27.0% | 468,990 | -25.5% | 0.00% | 0.0% |
| Q1 2018 | $12,918,000 | -30.8% | 629,851 | -4.5% | 0.00% | 0.0% |
| Q4 2017 | $18,671,000 | -10.8% | 659,291 | -2.0% | 0.00% | -33.3% |
| Q3 2017 | $20,927,000 | +59.6% | 672,891 | +62.3% | 0.00% | +50.0% |
| Q2 2017 | $13,114,000 | +143.7% | 414,491 | +74.4% | 0.00% | +100.0% |
| Q1 2017 | $5,382,000 | +45.9% | 237,606 | +40.6% | 0.00% | – |
| Q4 2016 | $3,689,000 | -70.8% | 169,006 | -64.7% | 0.00% | -100.0% |
| Q3 2016 | $12,627,000 | +16.2% | 479,024 | -12.9% | 0.00% | +100.0% |
| Q2 2016 | $10,863,000 | – | 550,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Conrad N. Hilton Foundation | 63,481 | $7,847,000 | 100.00% |
| CPMG Inc | 2,896,901 | $358,115,000 | 55.16% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 140,000 | $17,307,000 | 26.62% |
| Corriente Advisors, LLC | 525,000 | $64,901,000 | 15.45% |
| DUMAC, INC. | 76,050 | $9,401,000 | 7.33% |
| MADDEN SECURITIES Corp | 35,152 | $4,345,000 | 2.80% |
| Biondo Investment Advisors, LLC | 113,692 | $14,055,000 | 2.69% |
| Duquesne Family Office | 749,897 | $92,702,000 | 2.50% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,754,000 | 2.44% |
| Integral Health Asset Management, LLC | 50,000 | $6,181,000 | 1.84% |